These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18057310)

  • 1. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision.
    Andress DL
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):179-83. PubMed ID: 18057310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: can we influence patient-level outcomes?
    O'Shea S; Johnson DW
    Nephrology (Carlton); 2009 Jun; 14(4):416-27. PubMed ID: 19563384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [News in the management of calcium and phosphorus metabolism disorders for patient treated by hemodialysis].
    Van Overmeire L; Delanaye P; Krzesinski JM
    Rev Med Suisse; 2005 Aug; 1(30):1960-5. PubMed ID: 16200940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle.
    Al Aly Z; González EA; Martin KJ; Gellens ME
    Am J Nephrol; 2004; 24(4):422-6. PubMed ID: 15308874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Guideline for the management of chronic kidney disease-related mineral and bone disorders (CKD-MBD)].
    Kakuta T
    Clin Calcium; 2007 May; 17(5):752-9. PubMed ID: 17471006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD).
    Goldsmith DJ; Massy ZA; Brandenburg V
    Semin Nephrol; 2014 Nov; 34(6):660-8. PubMed ID: 25498384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies for renal bone disease.
    Lindberg J
    Nephrol News Issues; 2001 Aug; 15(9):21-4. PubMed ID: 12099184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.
    Lundquist AL; Nigwekar SU
    Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):120-6. PubMed ID: 26785065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the management of renal osteodystrophy in children.
    Salusky IB; Ramirez JA; Goodman WG
    Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):580-7. PubMed ID: 7859020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
    Goto S; Fukagawa M
    Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy for ROD and measurement of the bone mass].
    Yamamoto I; Kawamura Y; Hirano K; Hayakawa H; Shigematu T
    Clin Calcium; 2004 Dec; 14(12):83-8. PubMed ID: 15577179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent secondary hyperparathyroidism.
    Ağbaht K; Güllü S
    Acta Clin Belg; 2011; 66(2):149. PubMed ID: 21630618
    [No Abstract]   [Full Text] [Related]  

  • 15. Secondary hyperparathyroidism in chronic kidney disease: clinical consequences and challenges.
    Michael M; Garcia D
    Nephrol Nurs J; 2004; 31(2):185-94; quiz 195-6. PubMed ID: 15114799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
    Okada N; Tsubakihara Y
    Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for the altered mineral metabolism of chronic kidney disease: implications for vascular calcification.
    Saab G; Whaley-Connell AT; Khanna R; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Dec; 1(2):107-12. PubMed ID: 19124399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in the prevention of cardiovascular morbidity and mortality in end-stage renal disease: role of anemia, hyperparathyroidism and calcifications].
    Del Vecchio L; Pozzoni P; Limardo M; Caruso S; Fortunato M; Pontoriero G; Locatelli F
    G Ital Nefrol; 2007; 24 Suppl 38():25-32. PubMed ID: 17922444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal osteodystrophy].
    Pols HA; Birkenhäger-Frenkel DH; Birkenhäger JC
    Ned Tijdschr Geneeskd; 1991 Jul; 135(27):1213-7. PubMed ID: 1861752
    [No Abstract]   [Full Text] [Related]  

  • 20. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.